Animal models are compelling that activating the beta-adrenergic pathway (via stress) results in tumor growth and metastasis. Beta-blockers blunt this effect in animals. All of Us could design a randomized intervention trial to test this potential benefit in humans. An observational approach could also be taken with careful attention to pharmacoepi principles and biases such as confounding by indication.
In animal models, stress is a trigger for tumor growth and metastasis, yet we have not adequately addressed this question in human cancer patients or survivors.
All of Us could longitudinally assess the biological experience of psychosocial stress (via biomarker or wearable technology) at specified times in the cancer survivorship period, and conduct an analysis of time to recurrence or time to death.